'Copies ml' presentation slideshows

Update of Antiretroviral Agents in Adults and Adolescents 2008

Asso.Prof. Narin Hiransuthikul MD, MPH, PhD Dep. of Preventive & Social Medicine Faculty of Medicine Chulalongkorn UNiversity. Update of Antiretroviral Agents in Adults and Adolescents 2008. NOV 17, 2008. Management of HIV/AIDS (1).

1.12k views • 100 slides

Hot topics:

Hot topics:. Guidelines, Prevention and cure. Guidelines Update. EACS GUIDELINES UPDATE 9.1 - OCTOBER 2018. Recommended regimens (preferred) DTG/ABC/3TC DTG-TFV/FTC BIC/TAF/FTC RAL qd /bid- TFV/FTC Recommended regimens RPV/TFV/FTC DRV/c(r)/ TFV /FTC EFV/TDF/FTC(3TC), EFV-TAF /FTC.

614 views • 61 slides

Salvage Antiretroviral Therapy

Salvage Antiretroviral Therapy. Guiding Principles, Strategies and the Role of Resistance Testing. HIV: Case History.

398 views • 27 slides

Guidelines for the use of antiretroviral agents in HIV infections

Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS Society. Guidelines for the use of antiretroviral agents in HIV infections.

347 views • 22 slides

EQASs for TTI Diagnostics as Tool for Elucidating and Solving Problems of Commercial and In-house Tests

322 views • 20 slides

H. Zeichhardt 1,3 , V. Lindig 1,2 and H.-P. Grunert 1,2,3

311 views • 20 slides

H. Zeichhardt 1,3 , V. Lindig 1,2 and H.-P. Grunert 1,2,3

258 views • 20 slides

H. Zeichhardt 1,3 , V. Lindig 1,2 and H.-P. Grunert 1,2,3

292 views • 20 slides

H.-P. Grunert 1,2 , K.-O. Habermehl 1,2 , V. Lindig 1 and H. Zeichhardt 1,3

EQASs for Blood Borne Virus Genomes and BSE Prions from Cattle Brain and INSTAND Reference Materials. H.-P. Grunert 1,2 , K.-O. Habermehl 1,2 , V. Lindig 1 and H. Zeichhardt 1,3

287 views • 16 slides

ARTEMIS: Phase III study design

366 views • 16 slides

H.-P. Grunert 1,2 , K.-O. Habermehl 1,2 , V. Lindig 1 and H. Zeichhardt 1,3

EQASs for Blood Borne Virus Genomes and BSE Prions from Cattle Brain and INSTAND Reference Materials. H.-P. Grunert 1,2 , K.-O. Habermehl 1,2 , V. Lindig 1 and H. Zeichhardt 1,3

259 views • 16 slides

Qualification Panels for West Nile Virus RNA Tests

Qualification Panels for West Nile Virus RNA Tests . Mark Manak, Ph.D. Boston Biomedica, Inc. West Bridgewater, MA. SoGAT Langen, Germany July 3, 2003. WNV Controls/Panels. Panel/Controls Design Designed to closely mimic a true serum sample Cultured Virus from an infected individual

251 views • 15 slides

MONOI ANRS 136

A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression. MONOI ANRS 136. C Katlama, MA Valantin, M Algarte-Genin, C Duvivier,

251 views • 14 slides

Development of S tandard Reagents for WNV NAT

Development of S tandard Reagents for WNV NAT. M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA. WNV Human Disease Cases in Six Outbreaks 1999-2004 in the U.S. 2002 : documented Human to Human transmission

232 views • 14 slides

Boosted PI therapy: theoretical basis

Boosted PI therapy: theoretical basis. Drug concentration. treatment-limiting toxicity. Toxicity threshold. Therapeutic window. Efficacy threshold. viral rebound. 0. 0. 24. Time (hours). MaxCmin1 - HIV RNA <400 c/ml ITT - Exposed. 100. saquinavir/r (n=148 ). 80. % patients.

240 views • 14 slides

Protocol 004: Part II Design

Raltegravir in antiretroviraler Kombinationstherapie bei therapienaiven HIV-1 infizierten Patienten: 96-Wochen-Daten.

173 views • 12 slides